Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Receivables - Net: 2018-2025

Historic Receivables - Net for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $3.4 million.

  • China SXT Pharmaceuticals' Receivables - Net fell 19.70% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 19.70%. This contributed to the annual value of $3.4 million for FY2025, which is 11.08% up from last year.
  • China SXT Pharmaceuticals' Receivables - Net amounted to $3.4 million in FY2025, which was up 11.08% from $3.0 million recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Receivables - Net registered a high of $4.8 million during FY2021, and its lowest value of $2.9 million during FY2023.
  • In the last 3 years, China SXT Pharmaceuticals' Receivables - Net had a median value of $3.0 million in 2024 and averaged $3.1 million.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Receivables - Net slumped by 30.00% in 2023, and later grew by 11.08% in 2025.
  • Yearly analysis of 5 years shows China SXT Pharmaceuticals' Receivables - Net stood at $4.8 million in 2021, then fell by 14.27% to $4.1 million in 2022, then plummeted by 30.00% to $2.9 million in 2023, then climbed by 6.24% to $3.0 million in 2024, then increased by 11.08% to $3.4 million in 2025.